In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014

International Journal of Antimicrobial Agents

Volumn 46, Issue 6, 2015, Pages 674-681

  Biedenbach, Douglas J ^a   Arhin, Francis F ^b   Moeck, Gregory ^b   Lynch, Thomas F ^a   Sahm, Daniel F ^a  

^a International Health Management Associates   (United States)

^b The Medicines Company   (Canada)

Author keywords

Lipoglycopeptide; Skin and soft tissue infection; Surveillance

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; ORITAVANCIN; OXACILLIN; PENICILLIN DERIVATIVE; TETRACYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DILUTION; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; EUROPE; FOOD AND DRUG ADMINISTRATION; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; SKIN INFECTION; SKIN STRUCTURE INFECTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; UNITED STATES; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; EUROPE; GLYCOPEPTIDES; HUMANS; LINEZOLID; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; VANCOMYCIN;

EID: 84949563016     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.08.014     Document Type: Article

References (29)

1. N.E. Holmes, and B.P. Howden What's new in the treatment of serious MRSA infection? Curr Opin Infect Dis 27 2014 471 478
2. K.A. Rodvold, and K.W. McConeghy Methicillin-resistant Staphylococcus aureus therapy: past, present, and future Clin Infect Dis 58 Suppl. 1 2014 S20 S27
3. M.M. Huycke, D.F. Sahm, and M.S. Gilmore Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future Emerg Infect Dis 4 1998 239 249
4. E. Nannini, B.E. Murray, and C.A. Arias Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus Curr Opin Pharmacol 10 2010 516 521
5. P.K. Tosh, S. Agolory, B.L. Strong, K. Berlee, J. Finks, K. Hayakawa, and et al. Prevalence and risk factors associated with vancomycin-resistant Staphylococcus aureus precursor organism colonization among patients with chronic lower-extremity wounds in Southeastern Michigan Infect Control Hosp Epidemiol 34 2013 954 960
6. F. Rossi, L. Diaz, A. Wollam, D. Panesso, Y. Zhou, S. Rincon, and et al. Transferable vancomycin resistance in a community-associated MRSA lineage N Engl J Med 370 2014 1524 1531
7. L.D. Saravolatz, H. Pawlak, and L.B. Johnson In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediated S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA) Int J Antimicrob Agents 36 2010 69 72
8. F.F. Arhin, I. Sarmiento, and G. Moeck Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) Int J Antimicrob Agents 41 2013 397 398
9. V. Srinivasan, B.J. Metcalf, K.M. Knipe, M. Ouattara, L. McGee, P.L. Shewmaker, and et al. vanG element insertions within a conserved chromosomal site conferring vancomycin resistance to Streptococcus agalactiae and Streptococcus anginosus MBio 5 2014 e01386 e01414
10. E. Bouza, and A. Burillo Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains Int J Antimicrob Agents 36 2010 401 407
11. A. Tice Oritavancin: a new opportunity for outpatient therapy of serious infections Clin Infect Dis 54 Suppl. 3 2012 S239 S243
12. A. Belley, G.A. McKay, F.F. Arhin, I. Sarmiento, S. Beaulieu, I. Fadhil, and et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing Antimicrob Agents Chemother 54 2010 5369 5371
13. G.G. Zhanel, F. Schweizer, and J.A. Karlowsky Oritavancin: mechanism of action Clin Infect Dis 54 Suppl. 3 2012 S214 S219
14. A. Belley, F.F. Arhin, I. Sarmiento, H. Deng, W. Rose, and G. Moeck Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant Staphylococcus aureus infection Antimicrob Agents Chemother 57 2013 205 211
15. G.R. Corey, S. Good, H. Jiang, G. Moeck, M. Wikler, S. Green, and et al. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of Gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study Clin Infect Dis 60 2015 254 262
16. G.R. Corey, H. Kabler, P. Mehra, S. Gupta, J.S. Overcash, A. Porwal, and et al. Single-dose oritavancin in the treatment of acute bacterial skin infections N Engl J Med 370 2014 2180 2190
17. F.F. Arhin, I. Sarmiento, and G. Moeck In vitro activities of oritavancin and comparators against methicillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene Int J Antimicrob Agents 44 2014 65 68
18. L.R. Karaoui, R. El-Lababidi, and E.B. Chahine Oritavancin: an investigational lipoglycopeptide antibiotic Am J Health Syst Pharm 70 2013 23 33
19. G. Lin, G. Pankuch, P.C. Appelbaum, and K. Kosowska-Shick Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents Antimicrob Agents Chemother 58 2014 6251 6254
20. A. Markham Oritavancin: first global approval Drugs 74 2014 1823 1828
21. A. Belley, E. Meesham-Grenon, G. McKay, F.F. Arhin, R. Harris, T. Beveridge, and et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro Antimicrob Agents Chemother 53 2009 918 925
22. C. Vidaillac, J. Parra-Ruiz, and M.J. Rybak In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin Diagn Microbiol Infect Dis 71 2011 470 473
23. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards - ninth edition. Document M07-A9 2012 CLSI Wayne, PA
24. V.S. Albrecht, M.J. Zervos, K.S. Kaye, P.K. Tosh, S. Arshad, K. Hayakawa, and et al. Prevalence of and risk factors for vancomycin-resistant Staphylococcus aureus precursor organisms in southeastern Michigan Infect Control Hosp Epidemiol 35 2014 1531 1534
25. F.F. Arhin, G. Moeck, D.C. Draghi, C.M. Pillar, and D.F. Sahm Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008 Int J Antimicrob Agents 36 2010 474 476
26. R.E. Mendes, D.J. Farrell, H.S. Sader, R.K. Flamm, and R.N. Jones Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13) J Antimicrob Chemother 70 2015 498 504
27. R.E. Mendes, H.S. Sader, R.K. Flamm, D.J. Farrell, and R.N. Jones Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program Antimicrob Agents Chemother 58 2014 2921 2924
28. I. Morrissey, H. Seifert, R. Canton, P. Nordmann, S. Stefani, A. MacGowan, and et al. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011 J Antimicrob Chemother 68 2013 164 167
29. C. Silva-Costa, A. Friães, M. Ramirez, J. Melo-Cristino Portuguese Group for the Study of Streptococcal Infections Differences between macrolide-resistant and -susceptible Streptococcus pyogenes: importance of clonal properties in addition to antibiotic consumption Antimicrob Agents Chemother 56 2012 5661 5666